Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M160,356Revenue $M11,202Net Margin (%)45.5Z-Score9.2
Enterprise Value $M163,747EPS $1.8Operating Margin %58.6F-Score8
P/E(ttm))18.8Cash Flow Per Share $4.3Pre-tax Margin (%)56.7Higher ROA y-yY
Price/Book11.810-y EBITDA Growth Rate %0Quick Ratio1.8Cash flow > EarningsY
Price/Sales8.55-y EBITDA Growth Rate %8.2Current Ratio2.1Lower Leverage y-yN
Price/Cash Flow17.4y-y EBITDA Growth Rate %176ROA % (ttm)35.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)72.0Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M1,509ROI % (ttm)15.0Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDRonald Muhlenkamp 2014-09-30 Add1.19%$85.07 - $109.43
($97.98)
$ 105.037%Add 42.59%206,350
GILDJoel Greenblatt 2014-09-30 Add0.21%$85.07 - $109.43
($97.98)
$ 105.037%Add 42.28%664,223
GILDDavid Dreman 2014-09-30 Buy 0.02%$85.07 - $109.43
($97.98)
$ 105.037%New holding, 2388 sh.2,388
GILDJohn Burbank 2014-09-30 Add0.01%$85.07 - $109.43
($97.98)
$ 105.037%Add 219.9%12,073
GILDDodge & Cox 2014-09-30 Buy $85.07 - $109.43
($97.98)
$ 105.037%New holding, 4800 sh.4,800
GILDKen Heebner 2014-09-30 Reduce-0.33%$85.07 - $109.43
($97.98)
$ 105.037%Reduce -8.77%1,560,000
GILDVanguard Health Care Fund 2014-09-30 Reduce-0.28%$85.07 - $109.43
($97.98)
$ 105.037%Reduce -76.79%379,200
GILDRay Dalio 2014-09-30 Reduce-0.07%$85.07 - $109.43
($97.98)
$ 105.037%Reduce -30.96%241,521
GILDKen Fisher 2014-09-30 Reduce-0.04%$85.07 - $109.43
($97.98)
$ 105.037%Reduce -21.74%763,423
GILDKen Heebner 2014-06-30 Buy 3.8%$65.48 - $83.02
($77.76)
$ 105.0335%New holding, 1710000 sh.1,710,000
GILDJulian Robertson 2014-06-30 Add2.98%$65.48 - $83.02
($77.76)
$ 105.0335%Add 28.55%443,911
GILDJoel Greenblatt 2014-06-30 Buy 0.48%$65.48 - $83.02
($77.76)
$ 105.0335%New holding, 466853 sh.466,853
GILDJohn Rogers 2014-06-30 Add0.25%$65.48 - $83.02
($77.76)
$ 105.0335%Add 60.78%638,734
GILDKen Fisher 2014-06-30 Add0.07%$65.48 - $83.02
($77.76)
$ 105.0335%Add 62.11%975,483
GILDRay Dalio 2014-06-30 Add0.06%$65.48 - $83.02
($77.76)
$ 105.0335%Add 41.22%349,821
GILDRonald Muhlenkamp 2014-06-30 Reduce-0.59%$65.48 - $83.02
($77.76)
$ 105.0335%Reduce -24.63%144,715
GILDVanguard Health Care Fund 2014-06-30 Reduce-0.21%$65.48 - $83.02
($77.76)
$ 105.0335%Reduce -39.79%1,633,700
GILDGeorge Soros 2014-06-30 Sold Out -0.04%$65.48 - $83.02
($77.76)
$ 105.0335%Sold Out0
GILDMariko Gordon 2014-06-30 Reduce-0.02%$65.48 - $83.02
($77.76)
$ 105.0335%Reduce -35.57%11,654
GILDJulian Robertson 2014-03-31 Add0.59%$68.55 - $83.95
($78.44)
$ 105.0334%Add 7.91%345,320
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GILD David Dreman 2014-09-302,38800.02New Buy
GILD Dodge & Cox 2014-09-304,80000New Buy
GILD John Burbank 2014-09-3012,07300.02+219.9%
GILD Ronald Muhlenkamp 2014-09-30206,3500.014+42.59%
GILD Joel Greenblatt 2014-09-30664,2230.040.7+42.28%
GILD John Rogers 2014-09-30643,8960.040.88+0.81%
GILD Julian Robertson 2014-09-30443,9110.0312.5
GILD Jean-Marie Eveillard 2014-09-3040000
GILD Ken Heebner 2014-09-301,560,0000.14.7-8.77%
GILD Mariko Gordon 2014-09-3010,36600.05-11.05%
GILD Mario Gabelli 2014-09-3042,60000.02-13.36%
GILD Ken Fisher 2014-09-30763,4230.050.17-21.74%
GILD Ray Dalio 2014-09-30241,5210.020.2-30.96%
GILD Vanguard Health Care Fund 2014-09-30379,2000.030.1-76.79%
Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BISCHOFBERGER NORBERT WEVP, R&D and CSO 2015-01-15Sell70,000$98.478.77view
Carter Paul RutherfordEVP Commercial Ops 2015-01-08Sell1,000$100.886.18view
Alton Gregg HEVP, Corp & Med Affairs 2015-01-08Sell5,000$100.896.17view
MARTIN JOHN CChairman and CEO 2015-01-05Sell150,000$95.1212.61view
Whitley Richard JamesDirector 2015-01-02Sell5,000$95.2212.49view
Carter Paul RutherfordEVP Commercial Ops 2015-01-02Sell1,000$95.0512.69view
Alton Gregg HEVP, Corp & Med Affairs 2015-01-02Sell7,000$95.1712.55view
Cogan John FrancisDirector 2014-12-22Sell26,000$95.0312.71view
MILLIGAN JOHN FPresident and COO 2014-12-08Sell146,823$106.260.8view
Carter Paul RutherfordEVP Commercial Ops 2014-12-01Sell2,000$100.027.09view

Press Releases about GILD :

    Quarterly/Annual Reports about GILD:

    News about GILD:

    Articles On GuruFocus.com
    Gilead Sciences Still has More Upside Jan 22 2015 
    Has Gilead Sciences Been Able To Maintain Its Lead Run In The Face Of Competition? Jan 22 2015 
    AbbVie Inc.’s Forthcoming Future Looks Optimistic Jan 13 2015 
    Weekly CEO Sells Highlight: Six Flags Entertainment Corp, Gilead Sciences Inc, Ingersoll-Rand PLC, C Jan 10 2015 
    J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
    Gilead Strikes Deal with CVS, Hits Back AbbVie Jan 06 2015 
    Alexion Pharma Downgraded Despite Progress in Pipeline Jan 05 2015 
    Is it Time to Sell Gilead Sciences? Dec 29 2014 
    Express Scripts Knocks Gilead’s Hepatitis C Drug in Favor of AbbVie Dec 22 2014 
    Is it Time to Sell Gilead Sciences? Dec 18 2014 


    More From Other Websites
    PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary Jan 26 2015
    Gilead Sciences: Time to Worry About a Tough 2015? Jan 26 2015
    Gilead to Allow Drug Makers to Produce Hepatitis C Treatment Jan 26 2015
    Gilead Expands Generic Sovaldi Pact to Add Investigational Pill Jan 26 2015
    2:21 am Gilead Sciences expands Hepatitis C generic licensing agreements to include investigational... Jan 26 2015
    Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic... Jan 26 2015
    Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic... Jan 26 2015
    Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic... Jan 26 2015
    Want To Control Drug Prices? Reject Price Controls Jan 26 2015
    German insurers win discounts on Gilead's Sovaldi Jan 24 2015
    German insurers win discounts on Gilead's Sovaldi Jan 24 2015
    The Zacks Analyst Blog Highlights: AbbVie, Gilead and Celgene - Press Releases Jan 22 2015
    Deutsche Bank Comments On Concerns Over Consensus Estimates For AbbVie And Gilead Sciences Jan 21 2015
    Gilead's John Martin Named Morningstar CEO of 2014 Jan 21 2015
    DMG MORI SEIKI AKTIENGESELLSCHAFT and DMG MORI SEIKI CO., LTD. to enter into Cooperation Agreement Jan 21 2015
    Morningstar Names John Martin of Gilead Sciences as its 2014 CEO of the Year Jan 21 2015
    Healthcare ETFs in Focus on Mixed JNJ Results - ETF News And Commentary Jan 21 2015
    Morningstar's 2014 CEO of the Year Jan 21 2015
    Podcast: What to Expect From the 4th Quarter Earnings Season Jan 21 2015
    Can Gilead Sciences Beat Hep-C Estimates? Jan 20 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK